Maria Carmela Pera
The Catholic University of America
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maria Carmela Pera.
Epileptic Disorders | 2012
Pierangelo Veggiotti; Maria Carmela Pera; Federica Teutonico; Daniela Brazzo; Umberto Balottin; C. A. Tassinari
Electrical status epilepticus in sleep (ESES)/continuous spikes andwaves during slow sleep (CSWS) is an age-related, self-limiting disorder characterised by epilepsy with different seizure types, global or selective neuropsychological regression, motor impairment, and a typical EEG pattern of continuous epileptiform activity for more than 85% of non-rapid eye movement (NREM) sleep. Although the first description of ESES/CSWS dates back to 1971, an agreement about the optimal treatment for this condition is still lacking. ESES/CSWS is rare (incidence is 0.2–0.5% of all childhood epilepsies) and no controlled clinical trials have been conducted to establish the efficacy of different antiepileptic drugs; only uncontrolled studies and case reports are reported in the literature. Treatment options for ESES/CSWS include some antiepileptic drugs (valproic acid, ethosuximide, levetiracetam, and benzodiazepines), steroids, immunoglobulins, the ketogenic diet, and surgery (multiple subpial transections). In this study, the comparative value of each of these treatments is reviewed and a personal therapeutic approach is proposed.
Neurology | 2014
Maria A. Rocca; Martina Absinta; Maria Pia Amato; Lucia Moiola; A. Ghezzi; Pierangelo Veggiotti; Ruggero Capra; Emilio Portaccio; Agnese Fiorino; Lorena Pippolo; Maria Carmela Pera; Mark A. Horsfield; Andrea Falini; Giancarlo Comi; Massimo Filippi
Objective: We combined structural and functional MRI to better understand the mechanisms responsible for cognitive impairment in pediatric patients with multiple sclerosis (MS). Methods: Brain dual-echo, diffusion tensor, 3D T1-weighted, and resting-state (RS) fMRI scans were acquired from 35 consecutive pediatric patients with MS and 16 sex- and age-matched healthy controls. Patients with abnormalities in ≥2 neuropsychological tests were classified as cognitively impaired. The regional distribution of white matter (WM) and gray matter (GM) damage was assessed using voxel-wise analyses. Default mode network (DMN) RS functional connectivity (FC) was also measured. Results: Sixteen patients (45%) were classified as cognitively impaired. Compared to cognitively preserved (CP) patients, cognitively impaired patients with MS had higher occurrence of T2 lesions as well as more severe damage to the WM and GM, as measured by atrophy and diffusivity abnormalities, in the posterior regions of the parietal lobes close to the midline (precuneus, posterior cingulum, and corpus callosum). Compared to the other study groups, they also showed reduced RS FC of the precuneus, whereas CP patients experienced an increased RS FC of the anterior cingulate cortex. A multivariable model identified diffusivity abnormalities of the cingulum and corpus callosum and RS FC of the precuneus as the covariates more strongly associated with cognitive impairment (C-index = 0.99). Conclusions: In pediatric patients with MS, cognitive dysfunction is associated with structural and functional abnormalities of the posterior core regions of the DMN. WM structural abnormalities co-occurring at this level are likely to be the substrate of such modifications.
Neuromuscular Disorders | 2015
Eugenio Mercuri; Richard S. Finkel; Jacqueline Montes; E. Mazzone; Maria Pia Sormani; M. Main; Danielle Ramsey; Anna Mayhew; Allan M. Glanzman; Sally Dunaway; Rachel Salazar; Amy Pasternak; Janet Quigley; Marika Pane; Maria Carmela Pera; M. Scoto; Sonia Messina; Maria Sframeli; Gian Luca Vita; Adele D'Amico; Marleen van den Hauwe; Serena Sivo; Nathalie Goemans; Petra Kaufmann; Basil T. Darras; Enrico Bertini; Francesco Muntoni; Darryl C. De Vivo
Highlights • The paper reports for the first time patterns of progression in type 2 and 3 SMA.• Different trajectories can be identified in ambulant and non-ambulant patients.• Age appears to be an important factor in determining trajectories of progression.
Neuromuscular Disorders | 2013
Marika Pane; Roberta Scalise; Angela Berardinelli; Grazia D’Angelo; Valeria Ricotti; Paolo Alfieri; Isabella Moroni; L. Hartley; Maria Carmela Pera; Giovanni Baranello; Michela Catteruccia; Tiziana Casalino; Domenico M. Romeo; Alessandra Graziano; Claudia Gandioli; Flaviana Bianco; E. Mazzone; Maria Elena Lombardo; M. Scoto; Serena Sivo; Concetta Palermo; Francesca Gualandi; Maria Pia Sormani; Alessandra Ferlini; Enrico Bertini; Francesco Muntoni; Eugenio Mercuri
The aim of this study was to assess neurodevelopmental profile in young boys affected by Duchenne muscular dystrophy and to establish the correlation between neurodevelopmental findings, and the type and site of mutations. A structured neurodevelopmental assessment (Griffiths Scale of Mental Development) was performed in 81 DMD boys before the age of four years (range: 7-47 months). The mean total DQ was 87 (SD 15.3). Borderline DQ (between 70 and 84) was found in 32% and DQ below 70 in 12.3% of the patients. Children with mutations upstream or in exon 44 had higher DQ than those with mutations downstream exon 44 which are associated with involvement of dystrophin isoforms expressed at high levels in brain. The difference was significant for total and individual subscale DQ with the exception of the locomotor subscale. Items, such as ability to run fast, or getting up from the floor consistently failed in all children, irrespective of the age or of the site of mutation. Our results help to understand the possible different mechanisms underlying the various aspects of neurodevelopmental delay, suggesting that the involvement of brain dystrophin isoforms may cause a delay in the maturation of coordination and dexterity.
PLOS ONE | 2017
Danielle Ramsey; M. Scoto; Anna Mayhew; M. Main; E. Mazzone; Jacqueline Montes; Roberto De Sanctis; Sally Dunaway Young; Rachel Salazar; Allan M. Glanzman; Amy Pasternak; Janet Quigley; Elizabeth Mirek; Tina Duong; Richard Gee; Matthew Civitello; Gihan Tennekoon; Marika Pane; Maria Carmela Pera; Kate Bushby; John W. Day; Basil T. Darras; Darryl C. De Vivo; Richard S. Finkel; Eugenio Mercuri; Francesco Muntoni
Recent translational research developments in Spinal Muscular Atrophy (SMA), outcome measure design and demands from regulatory authorities require that clinical outcome assessments are ‘fit for purpose’. An international collaboration (SMA REACH UK, Italian SMA Network and PNCRN USA) undertook an iterative process to address discontinuity in the recorded performance of the Hammersmith Functional Motor Scale Expanded and developed a revised functional scale using Rasch analysis, traditional psychometric techniques and the application of clinical sensibility via expert panels. Specifically, we intended to develop a psychometrically and clinically robust functional clinician rated outcome measure to assess physical abilities in weak SMA type 2 through to strong ambulant SMA type 3 patients. The final scale, the Revised Hammersmith Scale (RHS) for SMA, consisting of 36 items and two timed tests, was piloted in 138 patients with type 2 and 3 SMA in an observational cross-sectional multi-centre study across the three national networks. Rasch analysis demonstrated very good fit of all 36 items to the construct of motor performance, good reliability with a high Person Separation Index PSI 0.98, logical and hierarchical scoring in 27/36 items and excellent targeting with minimal ceiling. The RHS differentiated between clinically different groups: SMA type, World Health Organisation (WHO) categories, ambulatory status, and SMA type combined with ambulatory status (all p < 0.001). Construct and concurrent validity was also confirmed with a strong significant positive correlation with the WHO motor milestones rs = 0.860, p < 0.001. We conclude that the RHS is a psychometrically sound and versatile clinical outcome assessment to test the broad range of physical abilities of patients with type 2 and 3 SMA. Further longitudinal testing of the scale with regards change in scores over 6 and 12 months are required prior to its adoption in clinical trials.
Neuromuscular Disorders | 2016
Roberto De Sanctis; Giorgia Coratti; Amy Pasternak; Jacqueline Montes; Marika Pane; E. Mazzone; Sally Dunaway Young; Rachel Salazar; Janet Quigley; Maria Carmela Pera; Laura Antonaci; Leonardo Lapenta; Allan M. Glanzman; Danilo Tiziano; Francesco Muntoni; Basil T. Darras; Darryl C. De Vivo; Richard S. Finkel; Eugenio Mercuri
Highlights • This paper reports patterns of natural progression in type I SMA.• The HINE is used to capture motor developmental milestones in SMA.• Motor developmental milestones are rarely acquired in type I SMA infants.
Epilepsia | 2013
Maria Carmela Pera; Daniela Brazzo; Nausicaa Altieri; Umberto Balottin; Pierangelo Veggiotti
The aim of this study was to evaluate the long‐term cognitive outcome in children with continuous spikes and waves during slow wave sleep (CSWS syndrome).
Epilepsy Research and Treatment | 2012
Daniela Brazzo; Maria Carmela Pera; Marco Fasce; Grazia Papalia; Umberto Balottin; Pierangelo Veggiotti
Encephalopathy with status epilepticus during sleep (ESES) is an epileptic encephalopathy, as defined by the International League Against Epilepsy (ILAE) Task Force on Classification and Terminology, that is, a condition in which the epileptic processes themselves are believed to contribute to the disturbance in cerebral function. Clinical manifestations of ESES are heterogeneous: apart from different seizure types, they consist in combinations of cognitive, motor, and behavioural disturbances associated with a peculiar electroencephalographic pattern of paroxysmal activity significantly activated during slow sleep, which culminates in a picture of continuous spikes and waves during sleep (CSWS). The pathophysiological mechanisms underlying this condition are still incompletely understood. Establishing a clear-cut correlation between EEG abnormalities and clinical data, though interesting, is very complex. Computer-assisted EEG analyses especially if combined with functional magnetic resonance imaging (EEG-fMRI) and metabolic neuroimaging have recently emerged as useful approaches to better understand the pathophysiological processes underlying ESES. Treatment of ESES is not just limited to seizures control but it should be focused on controlling neuropsychological outcome through an improvement of the continuous epileptiform activity. General agreement on treatment guidelines is still lacking. Implementation of new techniques might allow a better understanding of the pathophysiology of ESES and could enhance therapeutics options.
Multiple Sclerosis Journal | 2015
Maria A. Rocca; Ermelinda De Meo; Maria Pia Amato; Massimiliano Copetti; Lucia Moiola; A. Ghezzi; Pierangelo Veggiotti; Ruggero Capra; Agnese Fiorino; Lorena Pippolo; Maria Carmela Pera; Andrea Falini; Giancarlo Comi; Massimo Filippi
We investigated the contribution of cortical lesions to cognitive impairment in 41 paediatric MS patients. Thirteen (32%) paediatric MS patients were considered as cognitively impaired. T2-hyperintense and T1-hypointense white matter lesion volumes did not differ between cognitively impaired and cognitively preserved MS patients. Cortical lesions number, cortical lesions volume and grey matter volume did not differ between cognitively impaired and cognitively preserved patients, whereas white matter volume was significantly lower in cognitively impaired versus cognitively preserved MS patients (p=0.01). Contrary to adult MS, cortical lesions do not seem to contribute to cognitive impairment in paediatric MS patients, which is likely driven by white matter damage.
Multiple Sclerosis Journal | 2016
Maria A. Rocca; Maria Elisa Morelli; Maria Pia Amato; Lucia Moiola; A. Ghezzi; Pierangelo Veggiotti; Ruggero Capra; Elisabetta Pagani; Emilio Portaccio; Agnese Fiorino; Lorena Pippolo; Maria Carmela Pera; Giancarlo Comi; Andrea Falini; Massimo Filippi
Objectives: We assessed global and regional hippocampal volume abnormalities in pediatric multiple sclerosis (MS) patients and their correlations with clinical, neuropsychological and magnetic resonance imaging metrics. Methods: From 53 pediatric MS patients and 18 healthy controls, global hippocampal volume was computed using a manual tracing procedure. Regional hippocampal volume modifications were assessed using a radial mapping analysis. MS patients with abnormal performance in three or more tests of a neuropsychological battery for children were classified as cognitively impaired. Results: Global hippocampal volume was reduced in MS patients compared with controls, but did not correlate with clinical, neuropsychological and magnetic resonance imaging measures. Compared to controls, MS patients experienced bilateral radial atrophy of the cornu ammonis, subiculum and dentate gyrus subfields as well as radial hypertrophy of the dentate gyrus subfield. Regional hippocampal volume modifications correlated with brain T2 lesion volume as well as attention and language abilities. Global hippocampal volume did not differ between cognitively impaired (n=12) and cognitively preserved MS patients. Compared to cognitively preserved, cognitively impaired MS patients had atrophy of the subiculum and dentate gyrus subfields of the right hippocampus. Conclusions: Hippocampal subregions have different vulnerability to damage in pediatric MS. Regional rather than global hippocampal involvement contributes to global cognitive impairment as well as to deficits of selected cognitive tests.